Similarly, Ozawa et al. [20] claimed that SMAD4 deletion was associated with activation of the MAPK/JNK pathway and resistance to cetuximab in head and neck squamous cell carcinoma. Here, MAPK8 is linked to head and neck squamous cell carcinoma.